Kymera Therapeutics (KYMR) Operating Income (2019 - 2025)
Historic Operating Income for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$92.5 million.
- Kymera Therapeutics' Operating Income fell 2828.05% to -$92.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$332.3 million, marking a year-over-year decrease of 6597.02%. This contributed to the annual value of -$261.6 million for FY2024, which is 5805.9% down from last year.
- Latest data reveals that Kymera Therapeutics reported Operating Income of -$92.5 million as of Q3 2025, which was down 2828.05% from -$84.6 million recorded in Q2 2025.
- Kymera Therapeutics' Operating Income's 5-year high stood at -$13.2 million during Q1 2021, with a 5-year trough of -$92.5 million in Q3 2025.
- In the last 5 years, Kymera Therapeutics' Operating Income had a median value of -$44.9 million in 2022 and averaged -$49.5 million.
- Its Operating Income has fluctuated over the past 5 years, first soared by 5000.78% in 2023, then crashed by 31815.97% in 2024.
- Over the past 5 years, Kymera Therapeutics' Operating Income (Quarter) stood at -$34.0 million in 2021, then decreased by 13.64% to -$38.6 million in 2022, then surged by 50.01% to -$19.3 million in 2023, then tumbled by 318.16% to -$80.8 million in 2024, then dropped by 14.57% to -$92.5 million in 2025.
- Its Operating Income stands at -$92.5 million for Q3 2025, versus -$84.6 million for Q2 2025 and -$74.4 million for Q1 2025.